New therapies in systemic lupus erythematosus-trials, troubles and tribulations-working towards a solution: Part 2-the politically incorrect version

Lupus

Volumn 18, Issue 2, 2009, Pages 101-103

  Wallace, D J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

CLINICAL TRIAL; EDITORIAL; HOSPITALIZATION; HUMAN; METHODOLOGY; STANDARD; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIRHEUMATIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 65349115354     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203308100843     Document Type: Editorial

References (2)

1. U.S. Food and Drug Administration. Guidance for industry on systemic lupus erythematosus developing drugs for treatment. US Department of Health and Human Services Web site. Available at: http://www.fda.gov/ohrms/dockets/dockets/ 05d0106/05d0106.htm. Accessed November 26, 2008
2. Isenberg, D, Gordon, C, Merrill, J, Urowitz, M. New therapies in systemic lupus erythematosus - trials, troubles and tribulations...working towards a solution. Lupus 2008; 17: 967-970 [editorial].